×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Kidney Cancer

Ryan McDonald
“Those who are doing well and are stable in terms of safety and tolerability can come into the office less often,” Dr. David R. Spigel, said. “(This is) a big win.”
 
Kristie L. Kahl
Dr. Brian Rini discussed the benefits of treating patients with relapsed or refractory renal cell carcinoma with the vascular endothelial growth factor tyrosine kinase inhibitor.
 
Conor Killmurray
Further follow up of the CheckMate-214 trial continues to show the superior long-term outcomes of Opdivo and Yervoy in treatment of patients with advanced renal cell carcinoma.
 
Jessica Skarzynski
Patients with advanced renal cell carcinoma may soon have a new option in the novel combination of Opdivo (nivolumab) and Cabometyx (cabozantinib).
 
Salima Witt
“I’m not going to give up on that just because of this pandemic. Health is most important, as it should be for us cancer survivors.”
 
Beth Fand Incollingo
Keytruda, an immunotherapy that treats a variety of adult cancers, can now be given at a higher dose that requires fewer visits to clinics for infusions to support social distancing during the COVID-19 pandemic.
Salima Witt
“I thought, you know what I have control right now: if I'm going to laugh, if I'm going to enjoy my family, or if I'm going to hide in a corner and cry all day. I'm not going to do that. I'm not going to let cancer do that to me.”
 
Katie Kosko
Once a patient progresses following initial treatment for kidney cancer, one expert says TKIs are the next step in therapy.
Katie Kosko
Different combinations of immunotherapy with chemotherapy are helping patients with renal cell carcinoma live longer.
 
Beth Fand Incollingo
The first study to look at cancer prevalence in transgender people and examine the health of transgender cancer survivors also found concerning health trends among transgender women and gender nonconforming people.
 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×